Business Wire

German Diabetes Clinic Increases Diabetic Retinopathy Screenings From Zero to Thousands After Implementing Eyenuk’s EyeArt AI Eye Screening System

Share

Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results of its expansion into Germany. Since adopting the EyeArt AI Eye Screening System in October 2018, Diabetes Center Mergentheim has screened thousands of diabetic patients, identifying approximately 10% with cases of referable diabetic retinopathy (DR). The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic retinopathy, the leading cause of vision loss in working-age adults.1

The EyeArt AI Eye Screening System makes in-clinic, real-time DR screening possible for any physician, enabling quick and accurate identification of patients with referable DR during a diabetic patient’s regular physician visit. Once the patient’s fundus images have been captured and submitted to the EyeArt System, the DR screening results are available to view and export to a PDF report in less than 60 seconds. The EyeArt System can free eye care specialists to focus on sight-saving treatment rather than screening for DR.

At Diabetes Center Mergentheim, more than 20,000 patients with diabetes are seen each year by diabetes care specialists. Before adopting the EyeArt System, patients would be referred to ophthalmologists outside of the clinic. This process placed undue burden on patients, and often they would never get the necessary screening.

“EyeArt AI Eye Screening System is helping us improve diabetic patient care. We can now offer eye screening right in our clinic, without dilation, while reducing wait time for screening and results,” said Prof. Dr. med. Thomas Haak, head physician of Diabetes Center Mergentheim and founding member and board director of DiabetesDE. “The accuracy and convenience of the EyeArt System is allowing us to identify and treat DR effectively and quickly. The patients with no referable DR feel good that they can be screened again in a year, and the patients with identified referable DR can feel good that their silently progressing retinopathy has been identified and will be treated before any loss of sight.”

About 7.5 million people in Germany have diabetes mellitus2, with over 2,500 patients going blind due to diabetic retinopathy each year. German guidelines recommend at-risk patients be screened annually, but this can be difficult with the shortage of eye doctors. By incorporating the EyeArt System into their clinic, Diabetes Center Mergentheim has addressed a serious complication associated with diabetes — the center now screens 10 to 15 patients per day for this vision-threatening condition.

“Last year, we began our partnership with Diabetes Center Mergentheim with a great promise, and now it is very gratifying to see the promise turning into real meaningful impact that EyeArt System’s adoption is making to the diabetes patients in the Bad Mergentheim community,” said Kaushal Solanki, founder and CEO of Eyenuk. “We are now replicating our success to clinics throughout Germany, taking us one more step further in realizing our mission to screen every eye in the world.”

About Diabetic Retinopathy (DR)

DR is a complication of diabetes caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). It is a silently progressing disease that at first may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The condition can develop in anyone who has type 1 or type 2 diabetes.3 It is estimated that one-third of all patients with diabetes will develop DR,4 making it the leading cause of vision loss in working-age adults.5

While DR screening is recommended for all diabetic patients, less than half get screened annually1, even in the developed world. Since diabetic patients outnumber ophthalmologists by 1,130 to 1 in Germany6, there are just not enough eye care specialists to meet the DR screening needs of the growing diabetic population. Even for those receiving an annual screening, ophthalmology appointment wait times for DR screening can be weeks or even months.

About the EyeArt AI Eye Screening System

The EyeArt AI Eye Screening System is the most extensively validated AI technology for autonomous detection of DR, tested in the real world on more than a half million patient visits globally with over 2 million images collected in real-world clinical environments. The EyeArt System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). The EyeArt System has CE marking in the European Union and a Health Canada license. In the U.S., the EyeArt System is limited by federal law to investigational use.

VIDEO: Learn more about the EyeArt AI Eye Screening System for Diabetic Retinopathy at the Diabetes Center Mergentheim

About Eyenuk Inc.

Eyenuk Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.

EyeArt is a registered trademark of Eyenuk Inc.

www.eyenuk.com

____________________

1   Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603
2

International Diabetes Federation (2017) IDF Diabetes Atlas, 8th edn. http://www.idf.org/diabetesatlas

3

https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms-causes/syc-20371611

4 Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. doi: 10.2337/dc11-1909
5 Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603
6

http://www.icoph.org/ophthalmologists-worldwide.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Capwell Communications
Ida Yenney
ida@capwellcomm.com
949-999-3303

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MSCI to Consult on a Potential Reclassification of Greece to Developed Market status27.1.2026 01:15:00 EET | Press release

MSCI Inc. (NYSE: MSCI) announced today the launch of a consultation on a proposal for the potential reclassification of Greece from Emerging Market status to Developed Market status in one step, with implementation targeted for the August 2026 Index Review. As part of the MSCI 2025 Market Classification Review, MSCI acknowledged that the Greek market made progress in aligning with the accessibility standards commonly observed in Developed Markets in Europe and that Greece also meets the Economic Development criteria for Developed Market status. However, at the time, Greece did not meet the Size and Liquidity persistency rule, which requires a minimum number of five companies to meet Developed Market Standard Index criteria over each of the last eight Index Reviews to consider an upward reclassification. MSCI treats European countries classified as Developed Markets as a single entity for index construction and maintenance purposes. This approach reflects the high degree of integration

The World’s Most Romantic Building: ESB Celebrates Valentine’s Day 2026 with NYC's Most Extravagant Date Night, Romantic Paint ‘ n Pour Classes, ‘Sleepless in Seattle’ Screenings, Proposal Package, and More27.1.2026 01:14:00 EET | Press release

Love is in the air at the “World’s Most Romantic Building.” The Empire State Building (ESB) today announced its romantic Valentine’s Day plans for couples in NYC, which include an over-the-top date night, Paint ‘n Pour classes, romantic movie screenings, a sunrise experience, and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126953627/en/ The World’s Most Romantic Building: ESB Celebrates Valentine’s Day 2026 with NYC's Most Extravagant Date Night, Romantic Paint ‘n Pour Classes, ‘Sleepless in Seattle’ Screenings, Proposal Package, and More “The Empire State Building Observation Deck has played a role in countless love stories throughout its 95-year history, from Hollywood movies to first dates and proposals,” said Dan Rogoski, observatory general manager. “Our world-famous Observatory Experience is the top NYC attraction for couples to make unforgettable memories on Valentine’s Day.” Empire for Two: For the third

Rimini Street to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 19, 202626.1.2026 20:46:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on February 19, 2026. The company will host a conference call and webcast on that date to discuss the fourth quarter and fiscal year 2025 results and the 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126188817/en/ Rimini Street to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 19, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, In

SES Acknowledges Fitch’s Rating Action and Reiterates Deleveraging Plan26.1.2026 20:07:00 EET | Press release

SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Fitch today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES continues to be rated investment grade by Fitch with a stable outlook. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. The Company also has a clear view of the multiple cash generating levers available to it that it believes can substantially support and accelerate the deleveraging plan. SES management will use these levers in a disciplined way and keep investors informed as they deliver on the strategic plan. Consistent with this plan, it remains management’s intention to delever, with a policy objective of reducing adjusted net leverage(1) to at least 3.0x or below. (1) Adjusted net leverage is defined as Adjusted Net Debt divided by Adjusted EBITDA. Adjusted Net Debt is

A2RL Drone Championship Sets the Pace for AI in Autonomous Flight26.1.2026 19:17:00 EET | Press release

The Abu Dhabi Autonomous Racing League (A2RL) Drone Championship delivered a decisive test of autonomous and human performance, as Technology Innovation Institute’s TII Racing set the fastest autonomous lap to win the AI Speed Challenge, while a human first-person-view (FPV) pilot, MinChan Kim – World FPV Champion, narrowly claimed victory in the Human vs AI finale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126735530/en/ A2RL Drone Championship Sets the Pace for AI in Autonomous Flight (Photo: AETOSWire) Organised by ASPIRE, the innovation acceleration arm of the Advanced Technology Research Council (ATRC), the event highlighted both the rapid progress of vision-based autonomy and the narrow margins that still separate human instinct from machine execution at speed. Held over two days on 21–22 January during UMEX, the A2RL Championship brought together leading AI research teams and world-class FPV pilots to compete a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye